Celldex Therapeutics (CLDX) After Phase 2 Trial Results As Valuation Questions Come Into Focus

Celldex Therapeutics (CLDX) is in focus after releasing topline results from its Phase 2 clinical trial in prurigo nodularis, a development that gives investors new information on a key pipeline program.

See our latest analysis for Celldex Therapeutics.

The Phase 2 readout arrives after a period of strong momentum in Celldex Therapeutics' stock, with a 90 day share price return of 19.11% and a year to date share price return of 42.48%. The 1 year total shareholder return of 75.09% contrasts with a more modest 13.89% total shareholder return over three years and a decline of 19.32% over five years.

If this trial news has your attention, it can be useful to see what else is moving in related areas and compare setups across 41 healthcare AI stocks

Celldex Therapeutics now trades at a sizeable discount to both analyst targets and one intrinsic fair value estimate after a strong run on trial news. Is the market being prudently cautious about risk, or is it being overly conservative about potential?

Preferred Price-to-Book of 6.6x: Is it justified?

Celldex Therapeutics currently screens as good value against its direct peers on a price-to-book basis, while looking expensive versus the broader US biotech industry. That split picture is what investors now need to weigh up after the latest trial update.

The preferred valuation yardstick here is the price-to-book ratio, or P/B, which compares the company’s market value to its net assets on the balance sheet. For Celldex Therapeutics, that figure stands at 6.6x. Management is running a clinical stage biopharmaceutical business with very limited revenue today, so much of the market value is tied to expectations around the pipeline rather than current earnings.

Against its closest peer group, a 6.6x P/B sits below the average multiple of 8.8x. That suggests the stock is priced more conservatively than similar companies that operate in comparable therapeutic areas and stage of development. Investors who focus on relative value within a tight peer set may see that gap as the key reference point for how the market currently views Celldex Therapeutics.

The picture changes when the comparison shifts to the wider US biotechs industry, where the average P/B is 2.3x. On that broader yardstick, Celldex Therapeutics trades at a premium multiple that is almost three times the sector average. The market is therefore assigning a materially richer valuation than the typical biotech stock, which implies higher expectations around the company’s antibody programs and future potential.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 6.6x (ABOUT RIGHT)

However, the Celldex Therapeutics story still hinges on successful trial outcomes and ongoing funding needs, which could quickly change sentiment if either disappoints.

Find out about the key risks to this Celldex Therapeutics narrative.

Another view on Celldex Therapeutics using our DCF model

The SWS DCF model points to a very different picture for Celldex Therapeutics. With the stock at $38.49 and our estimate of future cash flow value at $101.60, it screens as heavily undervalued. If the market is this far below that estimate, what is being priced in?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Celldex Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 56 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on Celldex Therapeutics finely balanced between concern and optimism, it helps to review the numbers yourself and decide quickly where you stand. To see how the current setup reflects both potential upside and the risks investors are watching, start by weighing these 2 key rewards and 3 important warning signs

Looking for more ideas beyond Celldex Therapeutics?

If you are weighing what Celldex Therapeutics means for your portfolio, this is also a smart moment to broaden your watchlist with other focused opportunities.

• Spot potential value opportunities early by scanning companies that trade below what their fundamentals may support using the 56 high quality undervalued stocks.
• Build a stronger income stream by reviewing companies that feature higher yields and consistent payouts with the help of the 8 dividend fortresses.
• Strengthen your defensive side by looking through the 89 resilient stocks with low risk scores to find businesses that aim for resilience when conditions get tougher.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com